Ovarian Cancer
Showing NaN - NaN of 100
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Ovarian Cancer Trial in Worldwide (VS-6766, VS-6766 and Defactinib)
Recruiting
- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer
- avutometinib (VS-6766)
- avutometinib (VS-6766) and Defactinib
-
Scottsdale, Arizona
- +46 more
Dec 29, 2022
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)
Active, not recruiting
- Advanced Solid Malignancy
- +13 more
-
Los Angeles, California
- +33 more
Dec 22, 2022
Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or
Active, not recruiting
- Melanoma
- +8 more
- Pegilodecakin
- +9 more
-
Los Angeles, California
- +9 more
Nov 15, 2022
Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal
Recruiting
- Breast Cancer
- +15 more
- ATRC-101
- +2 more
-
Phoenix, Arizona
- +10 more
Sep 28, 2022
Biomarkers in Subjects With Untreated Solid Tumors
Completed
- Breast Cancer
- +12 more
- Blood Sample Collection
-
Phoenix, Arizona
- +118 more
Aug 31, 2022
NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- CPI-006
- +2 more
-
Tucson, Arizona
- +26 more
Aug 1, 2022
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
-
Anchorage, Alaska
- +55 more
Jul 25, 2022
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer Trial in United States (mRNA-2416, Durvalumab)
Terminated
- Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Ovarian Cancer
- mRNA-2416
- Durvalumab
-
Aurora, Colorado
- +8 more
Jul 7, 2022
Ovarian Cancer, Endometrial Cancer, Cervix Cancer Trial in Oklahoma City (SHetA2)
Recruiting
- Ovarian Cancer
- +2 more
-
Oklahoma City, OklahomaStephenson Cancer Center
Jul 7, 2022
Ovarian Cancer Trial in Oklahoma City (Vitamin D3)
Completed
- Ovarian Cancer
- Vitamin D3
-
Oklahoma City, OklahomaUniversity of Oklahoma Health Sciences Center
Apr 11, 2022
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY314, Combination Therapy: PY314 +
Recruiting
- Advanced Solid Tumor
- +8 more
- PY314
- Combination Therapy: PY314 + Pembrolizumab
-
Scottsdale, Arizona
- +12 more
Mar 28, 2022
Ovarian Cancer Trial in Oklahoma City (Unesbulin)
Active, not recruiting
- Ovarian Cancer
-
Oklahoma City, OklahomaUniversity of Oklahoma Health Sciences Center
Feb 21, 2022